3rd ESTRO Forum 2015 S87 Purpose/Objective: In vivo dosimetry (IVD) in brachytherapy (BT) is aimed to assess doses to organs at risk (OAR) by direct measurements. It is also an independent method to detect errors in dose delivery, and thus might be used as for patient QA of the whole BT process. Widely spread in external beam radiotherapy (EBRT), IVD in BT has faced some issues, mainly related to uncertainties due to high step gradients and detector positioning. In this study we present and analyze the results of in vivo dose determination in a urethral point with a group of HDR prostate patients (52 with Ir-192 and 10 with Co-60). Taking into account the uncertainties, the results and the system integration we evaluate the IVD system performance Materials and Methods: The electrometer (MultiDos, PTW) is integrated in the afterloader (MultiSource, Eckert & Ziegler BEBIG). The software to calibrate the dosimeter and to visualize the measured dose is integrated in the treatment console. The urethral probe (T9113, PTW) has a silicon diode in the tip of a rubber cable.To do the calibration we use a cylindrical phantom (Krieger phantom T9193, PTW). By means of a preconfigured plan in the MultiSource software the source is set in the Krieger phantom geometric center. Dose rate in the calibration point, set at 8 cm from the source position, is calculated through the source activity. The dose rate calculation takes into account the Krieger phantom's material (PMMA) and geometry which results in a factor 0.87 for Ir-192, and 0.93 for Co-60 compared with water and full scatter conditions. Despite dose rate at 8 cm is very small, the calibration shows a good signal to noise ratio (>40). We observe a sensitivity loss of about 0.75% per month. Uncertainties involved in the calibration has been established in other studies, and are around 7% (k=1 type B). To do in vivo measurements, after needles insertion the detector is set in the urethra into a Foley catheter, and it is carried to an intermediate position, halfway between prostate base and apex, where dose gradients are expected to be smooth. A control point is set in the TPS (HDRplus 3.0.6, E&Z BEBIG) representing the detector position using real time sagittal ultrasound images. Results: Measured dose deviation from that calculated with the TPS is in average -6.9%±4.0% (k=1 type A) for Ir-192 and -4.6%±3.1% (k=1 type A) for Co-60. Due to fact that we are using real time images for assessing the position of both needles and detector, these results show a better agreement than other previously published (Waldhäusl, 2005; Sharma, 2013). The negative systematic deviation might be caused by the effect of inter-needle attenuation, which is not taken into account in the TG-43 algorithm.
Conclusions:
Despite current 3D image-based dose calculation algorithms are more accurate than IVD for dose assessment of OARs, this integrated system provides a simple way to avoid mistakes in treatment administration. The uncertainties are considerably higher than those we are used to in EBRT, but still good enough to do a comprehensive patient QA. Purpose/Objective: High dose rate (HDR) brachytherapy treatment is widely practiced but lacks independent routine treatment delivery verification to identify potential errors and ensure patient safety. We report our initial clinical experience with a novel, non-invasive, position-sensitive source-tracking system based on a flat panel detector (FPD) for treatment verification in HDR prostate brachytherapy. Materials and Methods: The FPD was mounted in a standard operating theatre couch (BetaStar, Marquet) under a customised carbon fibre couch top assembly. Four prostate patients (8 treatment fractions) were included in this initial study. At treatment each patient was aligned on the couch with the target region centred over the sensitive imaging area of the FPD. Prior to treatment, three x-ray dwell position markers were inserted into selected catheters and a radiograph captured with the FPD to localise the implant relative to the detector. As the HDR source treatment dwells were delivered, images were acquired with the FPD and postprocessed to determine the position of the source inside the patient. The source positions determined by the tracking system were compared to the treatment plan to verify correct treatment delivery. Results: Measured source dwell positions confirmed correct transfer tube connection, source step size and patient/plan selection. The mean linear distance between measured and planned positions (example fraction shown in Figure 1 ) was 1.8mm (range 0.7 to 3.9mm) after rigid registration with the plan. The average measured dwell step size for all measured catheters was 2.5mm (range 1.9 to 3.1mm; s.d. 0.2mm). The absolute position of the measured source dwells was evaluated by comparing the measured dwell positions with xray dwell position markers from the pre-treatment radiograph (mean 3.9mm, range 0.8 to 9.9mm). This, together with the implanted gold fiducial markers, visible on the radiograph, provided verification of programmed treatment indexer length and therefore delivery to the correct anatomical location. The total impact on procedure time was less than 15 minutes. Conclusions: The novel, non-invasive HDR brachytherapy treatment verification system was implemented clinically, providing verification of many treatment parameters by tracking the position of the HDR source as treatment was delivered. The novel application of the FPD allows verification that treatment delivery was free of most potential human related errors identified in ICRP 97. This concept and system will meaningfully improve safety standards by allowing routine treatment verification in HDR brachytherapy across a range of clinical applications. Figure 1 : Measurement vs plan for 2 dwells in each of 5 catheters from a patient treatment fraction. A subset of all measurements is shown.
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